1. Home
  2. CLLS vs RMM Comparison

CLLS vs RMM Comparison

Compare CLLS & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • RMM
  • Stock Information
  • Founded
  • CLLS 1999
  • RMM 2019
  • Country
  • CLLS France
  • RMM United States
  • Employees
  • CLLS N/A
  • RMM N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • RMM Trusts Except Educational Religious and Charitable
  • Sector
  • CLLS Health Care
  • RMM Finance
  • Exchange
  • CLLS Nasdaq
  • RMM Nasdaq
  • Market Cap
  • CLLS 299.0M
  • RMM 265.5M
  • IPO Year
  • CLLS 2007
  • RMM N/A
  • Fundamental
  • Price
  • CLLS $3.79
  • RMM $14.06
  • Analyst Decision
  • CLLS Buy
  • RMM
  • Analyst Count
  • CLLS 1
  • RMM 0
  • Target Price
  • CLLS $4.00
  • RMM N/A
  • AVG Volume (30 Days)
  • CLLS 151.7K
  • RMM 66.5K
  • Earning Date
  • CLLS 11-03-2025
  • RMM 01-01-0001
  • Dividend Yield
  • CLLS N/A
  • RMM 7.33%
  • EPS Growth
  • CLLS N/A
  • RMM N/A
  • EPS
  • CLLS N/A
  • RMM 0.96
  • Revenue
  • CLLS $63,438,000.00
  • RMM N/A
  • Revenue This Year
  • CLLS N/A
  • RMM N/A
  • Revenue Next Year
  • CLLS $66.76
  • RMM N/A
  • P/E Ratio
  • CLLS N/A
  • RMM $15.55
  • Revenue Growth
  • CLLS 223.09
  • RMM N/A
  • 52 Week Low
  • CLLS $1.10
  • RMM $12.32
  • 52 Week High
  • CLLS $3.83
  • RMM $16.10
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 65.98
  • RMM 58.61
  • Support Level
  • CLLS $3.36
  • RMM $13.98
  • Resistance Level
  • CLLS $3.60
  • RMM $14.22
  • Average True Range (ATR)
  • CLLS 0.24
  • RMM 0.13
  • MACD
  • CLLS 0.02
  • RMM -0.01
  • Stochastic Oscillator
  • CLLS 96.95
  • RMM 42.86

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About RMM RiverNorth Managed Duration Municipal Income Fund Inc.

RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

Share on Social Networks: